CepTor Corporation Seeks Approval To Initiate Clinical Trial Of Myodur For Muscular Dystrophy; Submits IND Complete Response To FDA

HUNT VALLEY, Md.--(BUSINESS WIRE)--Sept. 12, 2006--CepTor Corporation (OTCBB:CEPO), a biopharmaceutical company focusing on cell-targeted therapeutic products for neuromuscular and neurodegenerative diseases, today announced that it submitted an Investigational New Drug (IND) Complete Response on August 29 to the Food and Drug Administration (FDA) in order to gain approval to move Myodur into human trials for boys suffering from Duchenne muscular dystrophy. The Company initially submitted the IND last January 12th but was informed by the FDA on February 7th that it had been put on hold pending the satisfactory response to agency questions. Those questions were received by the Company from the FDA on March 17th and the Complete Response was submitted August 29th. According to the PDUFA legislation, CepTor expects to know if it has clearance to move Myodur into the clinic by September 30th.